These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 14686963

  • 21. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 22. Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study.
    Wirth A, Scholze J, Sharma AM, Matiba B, Boenner G.
    Diabetes Obes Metab; 2006 Nov; 8(6):674-81. PubMed ID: 17026492
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 24. Sibutramine in overweight/obese hypertensive patients.
    Sharma AM.
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S20-3. PubMed ID: 11916102
    [Abstract] [Full Text] [Related]

  • 25. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A, Krause J.
    JAMA; 2001 Sep 19; 286(11):1331-9. PubMed ID: 11560538
    [Abstract] [Full Text] [Related]

  • 26. Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
    Seagle HM, Bessesen DH, Hill JO.
    Obes Res; 1998 Mar 19; 6(2):115-21. PubMed ID: 9545017
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR, Long B, Crow S, Styne D, Sothern M, Vargas-Rodriguez I, Harris L, Walch J, Jasinsky O, Cwik K, Hewkin A, Blakesley V, Sibutramine Adolescent Study Group.
    Pediatrics; 2007 Jul 19; 120(1):e147-57. PubMed ID: 17576783
    [Abstract] [Full Text] [Related]

  • 28. Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients.
    Ferland A, Poirier P, Sériès F.
    Eur Respir J; 2009 Sep 19; 34(3):694-701. PubMed ID: 19357147
    [Abstract] [Full Text] [Related]

  • 29. Sibutramine produces dose-related weight loss.
    Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB.
    Obes Res; 1999 Mar 19; 7(2):189-98. PubMed ID: 10102256
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z, Placha G.
    J Hum Hypertens; 2005 Sep 19; 19(9):737-43. PubMed ID: 15905888
    [Abstract] [Full Text] [Related]

  • 31. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT.
    Diabetes Obes Metab; 2005 May 19; 7(3):246-53. PubMed ID: 15811141
    [Abstract] [Full Text] [Related]

  • 32. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG, Egri Z.
    Clin Auton Res; 2005 Jun 19; 15(3):189-92. PubMed ID: 15944867
    [No Abstract] [Full Text] [Related]

  • 33. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E, Carruba MO.
    Drug Saf; 2003 Jun 19; 26(14):1027-48. PubMed ID: 14583064
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
    Halpern A, Leite CC, Herszkowicz N, Barbato A, Costa AP.
    Rev Hosp Clin Fac Med Sao Paulo; 2002 Jun 19; 57(3):98-102. PubMed ID: 12118266
    [Abstract] [Full Text] [Related]

  • 35. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug 19; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 36. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
    Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR.
    Int J Obes (Lond); 2007 Jan 19; 31(1):161-8. PubMed ID: 16652122
    [Abstract] [Full Text] [Related]

  • 37. [Sustained weight reduction after cessation of obesity treatment with Sibutramine].
    Wirth A.
    Dtsch Med Wochenschr; 2004 Apr 30; 129(18):1002-5. PubMed ID: 15131746
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Absence of cardiac valve dysfunction in obese patients treated with sibutramine.
    Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, Seaton TB, Patel B, Pekkarinen TA, Armstrong WF.
    Obes Res; 1999 Jul 30; 7(4):363-9. PubMed ID: 10440592
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.